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This thesis focuses on the modelling of residual risk of transfusion transmissible 
infections (TTIs)1,2 with emphasis on a resource constrained settings in sub-Saharan 
Africa.3,4 The Africa Society for Blood Transfusion Research Priorities (2008)5 in-
formed the basis of the studies undertaken in this thesis, focusing on research 
components rated high priority for the sub-Saharan Africa. The need to monitor 
the residual risk of TTIs has always been a major priority in transfusion medicine.6–8 
We first explored the HIV burden and dynamics in the general and blood donor 
populations and how this impacts the blood safety programme in Zimbabwe as 
described in Chapters 2 and 3.1,3 The first level for blood safety management is 
to identify low-risk populations for TTIs and target these for blood donations 
purposes. In order to do this, a clear understanding of the TTIs dynamics in the 
general and blood donor populations is appropriate. In the blood donors, it is also 
important to track and compare the TTIs from the new and repeat donations, 
as these tend to differ. A comparison of TTIs residual risk estimation models ap-
plicable for Zimbabwean blood service data was investigated and presented in 
Chapter 4.2 We determined the transfusion residual risk estimates for viral TTIs, 
human immunodeficiency syndrome (HIV), hepatitis B virus (HBV), and hepatitis C 
virus (HCV) in Zimbabwe based on application of three residual risk models devel-
oped for different settings. Determining accurate and understanding the residual 
risk estimates will assist the National Blood Service Zimbabwe in designing and 
implementing appropriate risk management strategies to optimise blood safety. 
In Chapter 5,9 a novel methodological approach is presented to estimate the risk 
of TTIs by travelling blood donors to areas with endemic or an ongoing emerging 
infectious diseases. The TTIs risk challenges posed by travelling donors is now a 
common global phenomenon, which affects both the developed and developing 
countries. We developed a generic and systematic model to assess this TTIs risk 
of emerging infectious diseases from travelling donors. The model will assist au-
thorities in blood transfusion services settings to proactively assess the traveller’s 
TTIs risk on their domestic blood supply and institute evidence-based measures to 
mitigate the posed risk. In Chapter 6, we describe the cost-effectiveness analysis of 
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introducing individual donation nucleic acid testing (ID-NAT) testing in addition to 
serologic testing in Zimbabwe. There is an intention within the National Blood Ser-
vice Zimbabwe to consider the addition of ID-NAT to further enhance blood safety 
but being cost-sensitive to implications of this intervention as investigated in our 
study. In Chapter 7,10 we describe a systematic approach to assess blood services 
institutional research capacity that will enable the generation of local evidence to 
inform evidence based decision making for their context. Currently, there is limited 
published evidence from sub-Saharan Africa blood services that informs their 
blood transfusion policies and practices as they currently rely on evidence gener-
ated from predominately western settings. The capacity to generate local evidence 
would require that the blood services initially build their research capacity. This 
research capacity development process is sadly missing in sub-Saharan Africa and 
our published tool, successfully piloted at National Blood Service Zimbabwe, will 
assist the blood services to assess their institutional research capacity.
Overall, the thesis main objective was to assess how the blood safety in Zimba-
bwe can be safeguarded through risk modelling of TTIs and the research questions 
explored were:
– How general and blood donor populations TTIs data can be jointly used to 
safeguard blood supply and monitoring dynamics of the infections?
– What is the residual risk of TTIs in Zimbabwe? What are the appropriate models 
to use in resource-limited settings?
– Can a model be developed to assess the risk of transfusion posed by travelling 
blood donors?
– What is the cost-effectiveness of adding ID-NAT to serologic test in a resource 
limited setting with high burden of the TTIs?
– How can blood services in resource-constrained settings assess their research 
capacity for enhanced evidence based blood safety interventions?






The general themes of this thesis are several fold. Firstly, the assessment of HIV 
burden in general and blood populations, and its implications on the blood safety 
programme, especially on the blood donor management. Secondly, the studies 
focused on the TTIs residual risk and travellers’ risk modelling focusing mainly on 
resource limited setting. Lastly, we examined the implications of our studies for 
blood services (research capacity) and transfusion patients (cost effectiveness) 
with focus on sub-Saharan Africa settings.
HIV in general and blood donor populations – implications on blood safety
Our studies looked at these two populations (general and blood donor) HIV 
changes over two periods and examined the possible impact on blood safety in 
Zimbabwe. There is need to understand the epidemiological context of TTIs in 
both populations as it is critical to ensure safer blood donations. Past studies have 
shown that Zimbabwe is categorized as a country with a generalized epidemic of 
HIV.11–17 Comparison of HIV data in general and donor populations can be key in 
responding to HIV burden18 especially in Zimbabwe, which does have a generalised 
HIV epidemic.19 As presented in Chapter 2, the variations in the change in HIV 
prevalence support studies that have shown that national trends mask the real 
differences hence the need of disaggregated analysis of data.20,21 The findings 
further support the view that the HIV epidemic in Zimbabwe is heterogeneous 
and these variations warrant a data driven focused approach in HIV programming. 
The provincial variations in HIV changes may be due to the increase in prevalence 
in geographic locations that are closer to a boarder or are situated around a 
highway from boarder. In other cases this has been attributed to higher internal 
and inter-country migration due to economic pressures. The decline in prevalence 
among young woman in age groups 15-39 years may suggest a reduction in HIV 
incidence. All these HIV trends at population level are important in informing the 
blood safety programming as risky areas would be avoided and safer donor groups 
will be targeted for recruitment. The presented donor management factor (general 
population HIV prevalence divided by the blood donor HIV seroprevalence) would 
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indicate progress or challenges in blood safety programme management. The 
concept of calculating HIV ratios (donor management factor in our study) between 
different sub-populations was also proposed by Borgdolff and coworkers22 in their 
study in Mwanza Region, Tanzania. We note that there have been limited studies in 
literature to utilise this ratio especially for blood safety management whereas this 
would greatly assist in blood donor management. The donor management factor 
decline that was observed for the Zimbabwe blood safety programme may be a 
reflection of increasing difficulties encountered in attracting safer blood donations. 
This would point to the need for more blood safety budgetary support in Zimbabwe 
for further public (donor) education, intensified donor selection and introduction 
of contemporary blood donation testing technologies such as ID-NAT and pathogen 
reduction. There is speculation (personal communications within National Blood 
Service Zimbabwe) that the generation born in an environment with HIV (those 
born from 1985) is now contributing to blood donations, hence this may be con-
tributing to HIV cases in the age group 16-20 years which is not driven primarily by 
risky behaviour exposure of the blood donor. This may represent a new dimension 
for the blood safety programme to deal with, given that 70% of blood donations in 
Zimbabwe are from this age group. This finding would not only have blood safety 
implications for Zimbabwe, but also for other settings with high proportions of 
young donors and with generalized HIV epidemic which is the actual situation for 
most sub-Saharan Africa countries. There is a need for a global multi-centre centre 
study to determine the generalizability of donor management factor in different 
settings and context. We were not able to extend our studies for similar analysis 
to include other key viral TTIs of HBV and HCV as the general population level data 
of these is not readily available in Zimbabwe. This should though be priority for 
future studies.
In summary, our findings points to the need for blood services to constantly 
undertake or participate in (sub) population based studies on current and emerg-
ing TTIs as this will help in optimising blood safety programmes. The within gender 
HIV changes noted are useful for designing a responsive and sustainable blood 
service programme that responds to the epidemiological dynamics within the 




to different settings and assess its utility as a global tool for assessing donor man-
agement by blood services. Our study was constrained as it focussed on HIV due 
to non-availability of data on HBV and HCV at population level and this should 
be prioritized in future studies. This will help especially in the monitoring of HBV 
burden in donated blood as currently this is presenting challenges in Zimbabwe 
and other sub-Saharan Africa settings. The multi-stakeholders in Zimbabwe need 
to be actively engaged so that in addition to the HIV module in the Zimbabwe 
Demographic Health Surveys, there are modules especially for HBV and HCV at 
population level as this will help to inform the blood safety programme. Another 
active area for research focus at both the general and blood donor populations 
level is the co-infections of viral TTIs as this will assist further in informing public 
health policies.
blood donor risk management of TTIs
In Chapter 3, we presented the National Blood Service Zimbabwe HIV risk manage-
ment strategy, which includes screening, and discarding of first-time donations, 
which are collected in blood packs without an anticoagulant (dry pack).1 The Zim-
babwean strategy deviates from other settings, especially from developed settings, 
which do not make use of new donations but only take a sample for testing. The 
concept of sample collection only for presenting higher risky blood donors is cur-
rently being investigated in Zimbabwe by assessing the views of donors (especially 
potential stigmatization in school settings) and the potential risk that the National 
Blood Service Zimbabwe might be used as an HIV voluntary counselling and testing 
centre (see Appendix A3: Abstract 7). There is early evidence of such test-seeking 
behaviour among some of the blood donors and thereby compromising blood 
safety.1,8,23 In both first-time and repeat blood donations, the HIV seroprevalence is 
lower than in the general population,24,25 which indicates the efficacy of donor mo-
tivation and selection procedures by National Blood Service Zimbabwe. The overall 
residual risk estimates in first time and repeat donations were comparable and 
this finding is consistent with the findings of Shang and co-workers 23 who found 
a lower residual risk among Shenzhen first-time blood donors. This is in contrast 
with Western blood donor populations. They speculated that this might be due 
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to differing donor demographics and donation motivations in the population they 
studied. In Zimbabwe, just like Shenzhen, the donor population is relatively young, 
which differ markedly with, for example, Australia with a median donor age of 44 
years.23 The young donors are generally considered highly mobile and prone to risky 
behaviours, which may have the consequence for characterizing the risk profile of 
first-time and repeat donors. In high HIV prevalence settings, such as Zimbabwe the 
use of appropriate donor selection methods complemented with advanced testing 
technologies will improve blood safety. In South Africa where the HIV prevalence 
in the general population is 11.4%,26 the South Africa National Blood Service re-
ported their residual risks in first-time and repeat donors as 1:25,641 (3.9/100,000 
donations) and 1: 40,000 (2.5/100,000 donations), respectively based on the study 
by Heyns and co-workers.26 After ID-NAT introduction in 2005, the South Africa 
National Blood Service reported 27 that the residual transmission risk of window 
phase donations was estimated at 1:479,000, which indicates enhanced blood 
safety through implementation of an advanced testing technology. In another 
residual transmission risk of TTIs study in sub-Saharan Africa by Jayaraman and 
colleagues8 it was estimated that the risk of HIV transmission is 1:1,000 donations 
(1 infection per 1,000 units), which is high compared to the Zimbabwean data. 
This may be indicative of different risk management strategies required in the 
sub-Saharan Africa blood services, depending on variations in prevalence and also 
related differences in cost-effectiveness.
In summary, the results indicate that for HIV prevalence the risk management 
strategy is sufficiently working as the HIV relative risk was about three times in 
first time discarded donations compared to repeat usable donations. However, the 
residual risk estimates in both first-time and repeat donations were comparable 
and as have been observed in some studies elsewhere and this suggest the need 
for a cost-effectiveness analysis of the blood donor risk management strategies. 
It has also been argued that the National Blood Service Zimbabwe can consider 
collecting only a test tube blood sample (as opposed to collecting a full unusable 
dry pack) in situations of perceived (uncertain) higher risk donation, which does 
not warrant a blood donor deferral. However, this paradigm shift would require 




risk being used as a testing centre thereby eventually compromising blood safety. 
The current risk management model is Zimbabwe is primarily based on the HIV and 
there is need to have an integrated risk model that takes into account other TTIs 
(appendix a3, abstract 5). Our analysis has shown that the new donors in the age 
group of 45 years and above are not as safer as currently thought at NBSZ and the 
risk management guideline is being reviewed to reflect this. Similar observations 
were noted for the majority donation age group of 16-20 years were HIV cases are 
increasingly getting worrying. All these points to the need for the National Blood 
Service Zimbabwe to explore further safer options for blood donations and intensify 
on donor retention strategies so as to optimise donations from repeat donors. In 
this study we demonstrated that new donors in the younger age group contribute 
majority of HBV cases and how this can be managed without compromising blood 
supply in Zimbabwe remains open for further research work. There is need for 
implementation of risk-based decision-making framework in sub-Saharan Africa as 
part of overall blood safety initiatives.
Risk modelling of TTIs
As presented in Chapters 4, the residual risk estimates for Zimbabwe are low 
(1:10,000 – 1:1000), when compared to the majority of blood services in sub-
Saharan African countries, which have moderate levels of residual risk estimates 
(1:1000–1:100) to high (1≥1:100).8,28 However, residual risk estimates for sub-
Saharan Africa vary greatly as residual risk estimates for HIV have been estimated 
and ranges from 1 in 90,200 donations to 1 in 25,600 donations in a multinational 
collaborative study.7 The variation found in various studies estimates may be a 
reflection of the application of different residual risk models, data quality, or dif-
ferences in study coverage (facility / regional / national). All these factors will 
ultimately compromise the full understanding of the actual status and attempts to 
monitor and evaluate the effectiveness of blood safety measures in sub-Saharan 
African countries. Our study has provided a justification for the use of comparable 
residual risk models for use by regional health authorities, policy makers and deci-
sion markers.8 Blood Safety projects should include residual risk estimates as an 
indicator tool for monitoring and evaluation in the programme management, to 
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complement current measures for tracking seroprevalence trends. The Africa Soci-
ety for Blood Transfusion has commendably included residual risk assessment for 
blood transfusion services as part of its stepwise accreditation programme 29 and 
research initiatives 30–32 to promote and standardize the residual risk estimation in 
blood services in the region. We note that there is no universally accepted residual 
risk classification and there is a risk classification proposed by Calman,28 which 
could be considered for adoption. This residual risk classification was adopted by 
the Australian Red Cross Blood Service, which uses four published risk models, to 
determine residual risk estimates.33 The use of three models in this study identifies 
the challenges inherent in residual risk modelling. This is an opportune time for 
blood services to agree on a generic model(s), which can be used for estimating 
residual risk. Van Hulst and colleagues 34 and the online EUFRAT tool (for emerging 
infectious diseases), 35,36, have demonstrated the importance of such tools.
In summary, the three models applied (a classical incidence-window period 
risk model and two adapted version in China and Zimbabwe) provided comparable 
residual risk estimates. This process allowed us to determine appropriate residual 
risk estimates for HIV, HBV, and HCV that will be utilised to inform blood safety 
decision-making process in Zimbabwe. The approach we used can be utilised in 
comparable settings so that the generalizability of this approach can be made. 
There remains a question on how the risk estimates can be categorised so that 
non-risk modellers who are mainly the policy makers and decision makers are 
properly guided so that they can apply the results in informing blood safety pro-
gramming. Currently there is no consensus among blood health authorities on the 
risk categorisation process and this should be tackled in future studies.
In Chapter 5, we have demonstrated that it is feasible to estimate for any 
setting (developed and developing countries) the number of transmissions from 
travelling donors using the novel method we developed. We applied the travellers’ 
risk model to the chikungunya outbreak in Italy 37 and the Q fever outbreak in the 
Netherlands 15 as these have previously been analysed using EUFRAT for the trans-
fusion transmissible risk among the local residents.36 For chikungunya outbreak, we 
estimated the traveller’s risk for a one week visit as 0.1 per million (0.1 infections 




colleagues reported that during this outbreak, a 21-day deferral policy was imple-
mented nationally for all donors who had visited the risk area even for a few hours, 
although their acceptable cut-off risk is 1 in 380,000, which is much higher than our 
model’s estimate.37 Had the travellers’ risk model been available at that time, the 
policy might have been different. Chikungunya has only a short infectious period 
of 8 days, therefore, only a limited number of future infections are anticipated. 
The ability of the travellers’ risk model to generate the expected number of future 
infections allows decision makers to quantify the potential immediate impact of 
(in)action on transfusion safety. Application of the travellers’ risk model may assist 
blood establishments in harmonising risks posed by travelling donors.38 Several 
studies have shown that travellers do pose a risk39,40 which requires blood authori-
ties in both the developed and developing settings to have mechanisms in place to 
manage such risks.41,42 The limited number of generic model parameters required 
permits the model to be applied in very diverse settings including sub-Saharan 
Africa. This not only empowers public health decision-makers with an appropriate 
tool to objectively quantify the risk from traveling donors, but also provides a sound 
proactive basis for enhanced management and response to outbreak situations. In 
addition to our risk modelling efforts, there is need to enhance the risk modelling 
based on the developed framework for risk-based decision-making43–45 to assess 
utility in resource-limited settings in sub-Saharan Africa.
In summary, the generic model we developed can be implemented in different 
settings globally based on few carefully selected parameters. When we applied our 
model to two published outbreaks of Chikungunya in Italy and Q-fever in Nether-
lands we demonstrated the utility of our novel approach, which make a distinction 
of past and future infections estimations. This allows the health authorities to 
objectively assess their action options to respond to the risk threats. Our model 
will allow a standardised approach to traveller’s risk and hopefully will facilitate 
global harmonisation of travel related deferrals in different settings. A prospective 
application of the model in real-time outbreaks will allow us to further understand 
the model application and have feedbacks on experiences and lessons learnt.
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Implications for blood services and transfusion patients
We examined the implications of our studies especially for the sub-Saharan Af-
rica. One key aspect is for the blood services to be able to make evidence based 
decisions for the blood safety programme. As presented in the previous chapters, 
one such safety measure is to consider and implement new testing technologies. 
However, this comes at an additional cost. We investigated the cost-effectiveness 
implication of adding ID-NAT testing to the serologic testing of HIV, HBV, and HCV in 
Zimbabwe as have been done elsewhere for such interventions.46–49 As presented 
in Chapter 6, it was shown that the introduction of ID-NAT in addition to serologic 
tests would lower HBV, HCV, and HIV transmission risks and save an estimated 212 
quality adjusted life years (QALYs). The incremental cost-effectiveness ratio was 
estimated at US$17,774/QALY, a value far more than three times the gross national 
income (GNI) per capita for Zimbabwe.50 However, the use of this WHO threshold 
and its applicability in settings such as Zimbabwe warrants further attention, as this 
value in other developed settings would result in favourable decision. Although 
desirable, the implementation of ID-NAT in Zimbabwe will result in a significant 
increase in the unit cost of blood (fee-for-service),51 which is already considered 
expensive and unaffordable by the public sector hospitals. This would adversely 
affect the patient’s receiving transfusion services in Zimbabwe. Thus, although the 
introduction of NAT could further improve the safety of the blood supply, current 
evidence suggests that it cannot be considered cost-effective. It was noted that 
reducing the test costs for NAT will improve cost-effectiveness and National Blood 
Service Zimbabwe would need to pursue this route with NAT vendors and funders. 
In summary, our findings were unfavourable to the addition of ID-NAT based on 
the threshold of three times the GNI as recommended by WHO. We noted chal-
lenges of the applicability of this threshold in settings such as Zimbabwe where the 
GNI may be severely compromised. Focus should be made to undertake further 
investigations on this area.
In order for blood services in resource-constrained settings to be able to 
generate their evidence for decision making (as demonstrated in this thesis), it is 
desirable to have structured research capacity building process of the institutions. 




to review the research capacity of blood services as evidenced by a successful pilot 
application at National Blood Service Zimbabwe. It was noted that the National 
Blood Service Zimbabwe’s research policies and strategies are similar to those of 
academic institutions in Africa52,57,58 and in more well-resourced countries such 
as United Kingdom, Australia and the Netherlands55–58 but are focussed more on 
improving internal operations than on generating research that is relevant interna-
tionally. There are other research models especially in developed countries, which 
National Blood Service Zimbabwe and other blood services (Canada, Australia and 
United Kingdom) could also consider.55,56,59 Although there are these examples of 
other models of the organization transfusion medicine research, we have been 
unable to find in the literature detailed descriptions about how these models were 
planned and operate. We were also unable to find any models from low-medium 
income countries and it is not clear if those from well-resourced countries would 
be transferable to a setting with much fewer resources such as Zimbabwe. More 
publications in this area will stimulate more work and harmonization of research 
organization within blood services so that best practice guidelines can be devel-
oped and adopted.
ConClUsIon anD fUTURe PRosPeCTs
In conclusion, overall this thesis has demonstrated that the risk modelling of TTIs 
can be equally and gainfully applied in sub-Saharan Africa and this momentum 
needs be maintained. The HIV changes and patterns linkages have been established 
from general to blood donor populations. The use of donor management factor as 
a risk assessment and management ratio for blood safety has been demonstrated 
and can be potentially transferred to other settings. The viral TTIs (HIV, HBV, and 
HCV) residual risk estimates for Zimbabwe were determined and used to assess 
the blood safety implications, and these were generally low risk though there 
was demonstrated high HBV burden, which requires further attention. Applicable 
residual risk models and impact of blood donor subpopulations on residual risk 
estimates for sub-Saharan Africa were assessed and it was demonstrated that sub-
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Saharan Africa adapted model performed comparatively well with other published 
models. These viral TTIs residual risk estimates needs to be further monitored and 
compared across sub-Saharan Africa based on comparable data sets and similar 
models applications. The travellers’ risk model we developed can be applied glob-
ally, including sub-Saharan Africa. However, there is need to have this model 
applied prospectively in realtime emerging infections diseases outbreaks in sub-
Saharan Africa and other settings. This will enable further review and validation 
of the model. The review and validation outcomes will be used to inform further 
refinements of the travellers’ risk model. The cost-effectiveness analysis of ID-NAT 
introduction in addition to serologic testing in Zimbabwe was presented. Although 
our findings indicated that it was not cost-effective to implement ID-NAT there is 
need for comparative studies across sub-Saharan African blood services involving 
current (implementing) and prospective centres on NAT technology implementa-
tion. This will allow an assessment and applicability of the current thresholds for 
cost-effectiveness of health interventions for the sub-Saharan Africa as questioned 
in our study. A systematic and structured process was developed on how blood 
services in sub-Saharan Africa can review their research capacity. This will allow 
the sub-Saharan blood services to conduct research activities that meet interna-
tional standards and inform their local health policies and practices. Currently, 
they are predominantly relying on evidence generated from developed settings. 
The application of this research capacity assessment tool needs to be applied in 
other blood services in sub-Saharan Africa. This will allow the sub-Saharan African 
blood services to build their own critical mass of transfusion medicine researchers 
meeting international standards. These sub-Saharan African researchers pool will 
be able to further contribute in addressing the sub-Saharan Africa research priority 
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